Cutaneous Pseudolymphoma: A Brief Review and Report of a Case Treatment Using Rituximab

  • Akbar Mokhtarpour Neilagh School of Medicine, Urmia University of Medical Sciences, Iran
  • Mahdi Aghazadeh Barenji School of Medicine, Urmia University of Medical Sciences, Iran
  • Shahin Behrouz Sharif Faculty of Medicine, Tabriz University of Medical Sciences, Iran
Keywords: cutaneous pseudolymphoma, cutaneous lymphoid hyperplasia, rituximab


Cutaneous pseudolymphoma (C-PSL) is characterized by heterogenous lymphoproliferative processes contributing to skin lesions which histologically and clinically mimic malignant cutaneous lymphomas. It is of most importance to diagnose such case precisely and discriminate them from malignant lymphomas since treatment protocols are distinctive. Standard medical approaches for C-PSL includes elimination of causative factors, topical, intralesional and systemic steroids, hydroxychloroquine, and photodynamic therapy. Rituximab as an anti CD20 monoclonal antibody was used in this study to treat a patient with 8 years clinical features of pseudolymphoma with no positive response to routine medications. Follow up of almost more than 18 months revealed a successful treatment without noticeable side effects or disease recurrence.

Author Biographies

Akbar Mokhtarpour Neilagh, School of Medicine, Urmia University of Medical Sciences, Iran
Department of Dermatology
Mahdi Aghazadeh Barenji, School of Medicine, Urmia University of Medical Sciences, Iran
Department of Dermatology
Shahin Behrouz Sharif, Faculty of Medicine, Tabriz University of Medical Sciences, Iran
Department of Medical Genetic


1. Sequeira F, Jayaseelan E, Stephen J. (2014 Paraphenylenediamine-induced cutaneous pseudolymphoma. IJD. 2014;59[4]:424.
2. Nnebe NV, Woon C, Haines S, Dayton V, Weigel BJ. Cutaneous pseudolymphoma: an unusual presentation of a scalp mass. Pediatric blood & cancer. 2009;52[2]:283-5.
3. Stoll DM. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. Journal of the American Academy of Dermatology. 1983;8[5]:696-9.
4. Dragonetti E, Cianchini G, Mastrangelo L, Mellone P, Baldi A. Cutaneus pseudolymphoma: a case report. in vivo. 2004;18[5]:549-52.
5. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clinical Lymphoma Myeloma and Leukemia. 2011;11[3]:286-8.
6. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of clinical oncology. 1998;16[8]:2825-33.
7. Weiner GJ, editor. Rituximab: mechanism of action. Seminars in hematology; 2010: Elsevier.
8. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research. 2008;14[5]:1561-70.
9. Harjunpaa A, Junnikkala S, Meri S. Rituximab [anti-CD20] therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian journal of immunology. 2000;51[6]:634.
10. Reff ME, Carner K, Chambers K, Chinn P, Leonard J, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83[2]:435-45.
11. Van der Kolk L, Grillo‐López A, Baars J, Hack C, Van Oers M. Complement activation plays a key role in the side‐effects of rituximab treatment. British journal of haematology. 2001;115[4]:807-11.
12. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of clinical oncology. 2003;21[21]:3940-7.
13. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin. Cancer Res. h. 2009;15[3]:851-7.
14. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10[6]:588-96.
15. Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 2007;8[4]:361-2.
Case Report